3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Pain, Postoperative
3
Pain
2
Neoplasm Metastasis
2
Hematologic Neoplasms
2
Vesico-Ureteral Reflux
1
Ureteral Neoplasms
1
Supratentorial Neoplasms
1
Pain, Intractable
1
Nephrolithiasis
1
Neoplasms
1
Multiple Myeloma
1
Mucositis
1
Lymphoma
1
Liver Neoplasms
1
Leukemia
1
Leiomyoma
1
Kidney Neoplasms
1
Ileus
1
Chronic Pain
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Bone Marrow Failure Disorders
1
Anemia, Aplastic
1
Agnosia
1
Advanced Malignant Neoplasm
1
Interventions
pembrolizumab
14
Nivolumab
11
Ipilimumab
10
cabozantinib
6
Axitinib
6
belzutifan
5
Radiosurgery
5
atezolizumab
4
Sunitinib
4
palbociclib
3
lenvatinib
3
Surveys and Questionnaires
3
Radiotherapy
3
Pluvicto
3
Everolimus
3
Blood Specimen Collection
3
Biopsy
3
zimberelimab
2
pazopanib
2
cemiplimab
2
Therapeutics
2
Methods
2
Magnetic Resonance Spectroscopy
2
Irinotecan
2
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
2
trebananib
1
toripalimab
1
tocilizumab
1
temsirolimus
1
spartalizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Kidney Neoplasms
×
Morphine
×
1 year
×
Clear all
NCT06349668
2026-02-05
SMILe
University Hospital, Linkoeping
Phase 3
Recruiting
220 enrolled